Saved by the spinoff. Pfizer is looking to set up its Japanese R&D operation, previously slated for shutdown, as an independent company--with the help of a few investors, of course. The company may retain an equity stake in the lab, which focuses on developing pain relievers and digestive remedies.
Apparently Pfizer's close involvement in the spun-off lab is a sticking point with the potential investors--some want it, and some think the lab would be better off if it's more independent.
- read this pieceÂ from CNNMoney
Pfizer honcho details plans to boost sales. Report
Pfizer's future rests with biotech. Report
Pfizer goes public with R&D pipeline. Report
Troubled Pfizer blueprints biotech venture effort. Report